1-4 of 4
Arthur L. Burnett
Close
Sort by
Journal Articles

Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

Alan Anderson, Fuad El Rassi, Michael R. DeBaun, Modupe Idowu, Julie Kanter, Soheir Adam, Susanna Curtis, Darla Liles, Biree Andemariam, Morgan L. McLemore, Robert Sheppard Nickel, Poornima Ramadas, Jincy Paulose, Dramane I Laine, Mahmudul Khan, Deepika S. Darbari, Arthur L. Burnett
Journal: Blood
Blood (2022) 140 (Supplement 1): 1636–1638.
https://doi.org/10.1182/blood-2022-157004
Published: 2022
Journal Articles

How I treat priapism

Uzoma A. Anele, Brian V. Le, Linda M. S. Resar, Arthur L. Burnett
Journal: Blood
Blood (2015) 125 (23): 3551–3558.
https://doi.org/10.1182/blood-2014-09-551887
Published: 2015
Journal Articles

Trends In the Hospital Treatment of Sickle Cell Disease-Related Priapism In the United States: 1998 to 2007,

Onaopemipo B. Ajiboye, MD, MPH, Sophie Lanzkron, MD, MHS, Mary Catherine Beach, MD, MPH, Shawn M Bediako, PhD, Arthur L. Burnett, M.D., M.B.A., Carlton Haywood, Jr., PhD, MA
Journal: Blood
Blood (2011) 118 (21): 4195.
https://doi.org/10.1182/blood.V118.21.4195.4195
Published: 2011
Journal Articles

Chronic Phosphodiesterase Type 5 Inhibitor Therapy Reduces Priapic Activity in Transgenic Sickle Cell Mice: Restoring Nitric Oxide/Redox Balance in the Penis.

Arthur L. Burnett, M.D., M.B.A., Biljana Musicki, Ph.D., Hunter C. Champion, MD, PhD, Trinity J. Bivalacqua, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 576.
https://doi.org/10.1182/blood.V114.22.576.576
Published: 2009